Rafferty Asset Management LLC Buys 53,877 Shares of Kura Oncology, Inc. (NASDAQ:KURA)

Rafferty Asset Management LLC raised its stake in Kura Oncology, Inc. (NASDAQ:KURA - Free Report) by 58.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 145,614 shares of the company's stock after buying an additional 53,877 shares during the period. Rafferty Asset Management LLC owned about 0.19% of Kura Oncology worth $1,268,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in KURA. Barclays PLC grew its position in shares of Kura Oncology by 104.5% in the 3rd quarter. Barclays PLC now owns 165,484 shares of the company's stock valued at $3,234,000 after buying an additional 84,563 shares during the last quarter. SG Americas Securities LLC bought a new stake in shares of Kura Oncology in the 4th quarter valued at about $436,000. Moody Aldrich Partners LLC grew its position in shares of Kura Oncology by 42.3% in the 4th quarter. Moody Aldrich Partners LLC now owns 143,587 shares of the company's stock valued at $1,251,000 after buying an additional 42,712 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its position in shares of Kura Oncology by 11.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 16,489 shares of the company's stock valued at $144,000 after buying an additional 1,750 shares during the last quarter. Finally, Jennison Associates LLC bought a new stake in shares of Kura Oncology in the 4th quarter valued at about $623,000.

Kura Oncology Stock Performance

Shares of NASDAQ KURA traded down $0.08 during mid-day trading on Tuesday, hitting $5.56. The company had a trading volume of 213,769 shares, compared to its average volume of 1,194,724. The company has a market capitalization of $481.53 million, a price-to-earnings ratio of -2.36 and a beta of 0.50. Kura Oncology, Inc. has a 1 year low of $5.41 and a 1 year high of $23.48. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. The stock's 50-day moving average price is $6.26 and its 200-day moving average price is $8.24.

Kura Oncology (NASDAQ:KURA - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.15). The firm had revenue of $14.11 million during the quarter, compared to the consensus estimate of $39.08 million. On average, sell-side analysts forecast that Kura Oncology, Inc. will post -2.44 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the company. Barclays reduced their price target on Kura Oncology from $32.00 to $11.00 and set an "overweight" rating on the stock in a research report on Friday, May 2nd. BTIG Research lowered Kura Oncology from a "buy" rating to a "neutral" rating in a research report on Thursday, February 6th. Wall Street Zen lowered Kura Oncology from a "buy" rating to a "hold" rating in a research report on Friday, May 2nd. Cantor Fitzgerald upgraded Kura Oncology to a "strong-buy" rating in a research report on Tuesday, March 4th. Finally, Wedbush restated an "outperform" rating and set a $36.00 target price on shares of Kura Oncology in a research report on Tuesday, April 8th. Four investment analysts have rated the stock with a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, Kura Oncology currently has a consensus rating of "Moderate Buy" and an average price target of $24.50.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.